First Patients Dosed in Clinical Trial of Novel Lung and Ovarian Cancer Theranostic
Melbourne and Adelaide (Australia) – 21st September 2020. Telix announces first two patients dosed in phase I trial of lung & ovarian cancer theranostic
Telix Pharmaceuticals Limited is pleased to announce that the first two patients have been dosed in a phase I study of the novel lung and ovarian cancer theranostic APOMAB™, at the Royal Adelaide Hospital (‘RAH’). The clinical study which is being conducted by the Central Adelaide Local Health Network (‘CALHN’) is co-funded by Telix and strategic partner, AusHealth®.
The study, which is being led by RAH Cancer Clinical Trials Unit Head Professor Michael Brown is a two-arm trial of an antibody that targets the La/SSB protein (APOMAB™), initially labelled with Zirconium-89 (89Zr-APOMAB) to enable the biological and targeting properties of the agent to be evaluated using positron emission tomography (PET).
The target of APOMAB, the La/SSB protein, is specifically expressed by cancer cells that have been treated with chemotherapy and/or radiation, and the research objective of the study is to evaluate how well APOMAB is able to potentially deliver diagnostic and therapeutic targeted radiation to advanced lung or ovarian cancers.
To read the full ASX release please click here.
The Role of Patents in Drug Development – Telix in Australian Biotechnology Journal
5 October 2022 | Corporate Spotlight | Telix in Australasian Biotechnology Journal – The Role of Patents in Drug Development
First Patient in New Zealand Dosed with Illuccix® – Telix’s Prostate Cancer Imaging Agent
Melbourne – 30 September 2022. First Patient in New Zealand Dosed with Illuccix® – Telix’s Prostate Cancer Imaging Agent
Chinese NMPA Approves Study of Telix Kidney Cancer Imaging Candidate
Melbourne – 28 September 2022. Chinese NMPA Approves Study of Telix Kidney Cancer Imaging Candidate